On Monday, Sage Therapeutics Inc (NASDAQ: SAGE) was -3.30% down from the session before settling in for the closing price of $13.33. A 52-week range for SAGE has been $10.92 – $59.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 3395.58%. When this article was written, the company’s average yearly earnings per share was at 29.40%. With a float of $49.05 million, this company’s outstanding shares have now reached $60.04 million.
Considering the fact that the conglomerate employs 487 people, you should pay attention to its efficiency factor.
Sage Therapeutics Inc (SAGE) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Sage Therapeutics Inc stocks. The insider ownership of Sage Therapeutics Inc is 18.39%, while institutional ownership is 94.71%. The most recent insider transaction that took place on Aug 09 ’23, was worth 37,279. In this transaction Director of this company bought 2,000 shares at a rate of $18.64, taking the stock ownership to the 3,000 shares. Before that another transaction happened on May 09 ’23, when Company’s Director bought 1,000 for $50.50, making the entire transaction worth $50,500. This insider now owns 1,000 shares in total.
Sage Therapeutics Inc (SAGE) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2023, it has been observed that the corporation posted -2.46 earnings per share (EPS) during the time that was better than consensus figure (set at -2.5) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.64 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.80% during the next five years compared to -2.28% drop over the previous five years of trading.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
You can see what Sage Therapeutics Inc (SAGE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.05, a number that is poised to hit -1.65 in the next quarter and is forecasted to reach -4.83 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Compared to the last year’s volume of 1.01 million, its volume of 2.01 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 35.77%. Additionally, its Average True Range was 1.06.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 11.36%, which indicates a significant decrease from 29.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.17% in the past 14 days, which was higher than the 63.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.53, while its 200-day Moving Average is $22.92. Nevertheless, the first resistance level for the watch stands at $13.30 in the near term. At $13.70, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.91. If the price goes on to break the first support level at $12.69, it is likely to go to the next support level at $12.48. Now, if the price goes above the second support level, the third support stands at $12.08.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
There are 60,107K outstanding shares of the company, which has a market capitalization of 774.82 million. As of now, sales total 86,460 K while income totals -541,490 K. Its latest quarter income was 77,970 K while its last quarter net income were -32,710 K.
